The Targeted Therapies for Osteosarcoma via Six Major Pathways

Shuxing Wang; Quanlei Ren; Guoqing Li; Xiaoxuan Zhao; Xing Zhao; Zhen Zhang

doi:10.2174/1874467217666230821142839

The Targeted Therapies for Osteosarcoma via Six Major Pathways

Curr Mol Pharmacol. 2024;17(1):e210823220109. doi: 10.2174/1874467217666230821142839.

Authors

Shuxing Wang^{1

2}, Quanlei Ren^{1

2}, Guoqing Li^{1

2}, Xiaoxuan Zhao^{1

2}, Xing Zhao³, Zhen Zhang¹

Affiliations

¹ Department of Oncology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
² Xiangya School of Medicine, Central South University, Changsha, 410078, Hunan, China.
³ School of Automation, Central South University, Changsha, Hunan, China.

PMID: 37602543
DOI: 10.2174/1874467217666230821142839

Abstract

Osteosarcoma is the most common primary bone malignancy and has a high tendency of local invasion. Although a lot of studies have focused on chemotherapy and combination chemotherapy regimens in recent years, still, there is no particularly perfect regimen for the treatment of relapsed or metastatic OS, and the prognosis is still relatively poor. As a new therapeutic method, targeted therapy provides a new scheme for patients with osteosarcoma and has a wide application prospect. This article reviews the latest progress of targeted therapy for osteosarcoma, and summarizes the research on the corresponding targets of osteosarcoma through six major pathways. These studies can pave the way for new treatments for osteosarcoma patients who need them.

Keywords: AURKB; CCNE1/CDK2; CDK4/CDK6/FOXM1; MYC/CDK9; Osteosarcoma; PTEN/PI3K/AKT1/mTOR; Pathway; Targeted therapy; VEGFA/vascular endothelial cell growth factor receptor..

Publication types

Review

MeSH terms

Bone Neoplasms* / drug therapy
Bone Neoplasms* / pathology
Humans
Osteosarcoma* / drug therapy
Osteosarcoma* / metabolism
Osteosarcoma* / pathology
Prognosis